查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026818

抗癲癇藥物市場預測至2034年—按癲癇發作類型、給藥途徑、藥物代數、分銷管道和地區分類的全球分析

Antiepileptic Drugs Market Forecasts to 2034 - Global Analysis By Types of Seizures, Route of Administration, Drug Generation, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球抗癲癇藥物市場規模將達到 223 億美元，並在預測期內以 6.5% 的複合年成長率成長，到 2034 年將達到 369 億美元。

癲癇是一種神經系統疾病，其特徵是反覆發作且無法預測的癲癇發作，由大腦異常電活動引起。抗癲癇藥物透過調節大腦電活動發揮作用，預防或減少導致癲癇發作的異常衝動。抗癲癇藥物（AEDs）能夠穩定細胞膜、增強抑制性神經傳導物質（如GABA）、阻斷鈉通道、降低麩胺酸興奮性或調節鈣離子通道。

根據世界衛生組織（世衛組織）2023年2月9日發布的報告，全球每年有500萬人被診斷出患有癲癇。在高所得國家，估計每年每10萬人中有49人患有癲癇。

藥物研發進展

持續不斷的研發努力，透過發現新的製劑、新的作用機制和改進的給藥系統，徹底革新了抗癲癇治療領域。新一代抗癲癇藥物的問世旨在解決傳統治療方法面臨的挑戰，例如副作用和難以完全控制癲癇發作。此外，包括緩釋製劑在內的先進製劑，最佳化了給藥方案，提高了患者的依從性，並提升了整體治療效果。這些藥物研發的進步正在推動市場需求的成長。

副作用

常見的副作用包括頭暈、疲勞、認知障礙和情緒波動，這些都會顯著影響患者的生活品質。困難在於如何平衡控制癲癇發作的治療效果與這些副作用的耐受性。此外，副作用的出現會導致患者不滿、用藥依從性下降或治療中斷，可能降低抗癲癇藥物的療效。這些副作用是阻礙因素。

癲癇盛行率增加

癲癇是一種以反覆發作為特徵的神經系統疾病，影響著世界各地眾多人群。癲癇盛行率的上升是由多種因素造成的。首先，診斷技術的進步和人們對癲癇意識的提高促進了癲癇的檢出率。醫學知識和技術的進步提高了醫護人員準確診斷和分類癲癇的能力。此外，宣傳宣傳活動和教育計畫普及了癲癇的症狀和早期診斷的重要性，促使更多人尋求醫療協助。

社會偏見

儘管人們對這種神經系統疾病的了解日益增多，但社會上仍然存在根深蒂固的誤解，導致患者在尋求適當治療時猶豫不決。圍繞癲癇的偏見可能導致診斷和治療的缺失，因為有些人害怕受到社會評判或歧視，而選擇隱瞞病情或尋求醫療協助。這種不願公開談論癲癇的現象會助長錯誤訊息的傳播，阻礙患者獲得抗癲癇藥物提供的必要且有效的治療，並妨礙患者教育。這些因素都會抑制市場需求。

新冠疫情的影響

新冠疫情對自動體外心臟去顫器（AED）市場產生了重大影響。疫情凸顯了確保醫療體系韌性的重要性。遠端醫療解決方案和遠端患者監護受到重視，為癲癇管理開闢了新的途徑。此外，針對新冠肺炎神經系統併發症的研究和開發工作也間接促進了人們對癲癇及相關疾病的認知。同時，供應鏈中斷和經濟不確定性影響了AED的生產和分銷，進而影響了市場動態。

在預測期內，第三代產品預計將佔據最大的市場佔有率。

據估計，第三代抗癲癇藥物將佔據最大的市場佔有率。這些藥物，例如拉考沙胺、艾斯利卡西平和吡崙帕奈，在控制癲癇發作方面表現出更高的特異性和療效。第三代抗癲癇藥物通常針對新的分子通路，從而提供更廣泛的作用頻譜和更高的神經元活動調節選擇性。第三代抗癲癇藥物的關鍵特徵是注重最大限度地減少副作用和藥物交互作用，從而提高整體耐受性。這對於提高患者對治療方案的依從性尤其重要。

在預測期內，口服藥物領域預計將呈現最高的複合年成長率。

預計在預測期內，口服給藥領域將實現顯著成長。口服給藥是指以片劑、膠囊或液體的形式服用抗癲癇藥物，使藥物能夠便捷且有效率地透過胃腸道吸收。口服給藥途徑在製劑設計上具有柔軟性，能夠開發出緩釋製劑，使藥物隨時間逐漸釋放。這項特性有助於維持血液中藥物濃度的穩定，從而最佳化治療效果並最大限度地減少可能誘發癲癇發作的濃度波動。

市佔率最大的地區：

在預測期內，北美佔據了最大的市場佔有率，這主要歸功於其完善的醫療保健基礎設施、先進的醫學研究以及癲癇相關疾病的高發生率。該地區成熟的製藥產業以及對研發的大量投入，推動了抗癲癇治療領域的創新。此外，主要市場參與者的存在以及最尖端科技的應用，也鞏固了該地區在推進治療方案方面的主導地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將迎來盈利發展，這主要得益於公眾意識的提高、醫療基礎設施的改善以及癲癇相關疾病盛行率的上升。診斷方法的改進和患者教育的加強進一步推動了該地區對抗癲癇藥物的需求。此外，亞太地區人口的多樣性和龐大的患者群體也為從事抗癲癇藥物研發和銷售的製藥公司提供了巨大的成長機會。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球抗癲癇藥物市場：依癲癇發作類型分類

  • 局部性癲癇發作
  • 整體癲癇發作
  • 其他類型的癲癇發作

第6章 全球抗癲癇藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 其他給藥途徑

第7章 全球抗癲癇藥物市場：依藥物世代分類

  • 第一代
    • Carbamazepine
    • 苯妥英
    • 丙戊酸
    • 奧卡巴西平
    • 乙琥胺
    • 托皮拉馬特
    • Primidone
    • Phenobarbital
  • 第二代
    • Pregabalin
    • 拉莫三嗪
    • 左乙拉西坦
    • 魯非醯胺
    • 醋酸依斯卡巴西平
    • 拉考沙胺
    • 佩蘭小組
    • 唑尼沙胺
  • 第三代

第8章 全球抗癲癇藥物市場：依通路分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房
  • 其他分銷管道

第9章 全球抗癲癇藥物市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Eisai Co., Ltd.
  • Novartis AG
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Abbott
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Service, Inc.
  • Zogenix
  • Alkem Labs
  • SK Biopharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
Product Code: SMRC24680

According to Stratistics MRC, the Global Antiepileptic Drugs Market is accounted for $22.3 billion in 2026 and is expected to reach $36.9 billion by 2034 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.

According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.

Market Dynamics:

Driver:

Advancements in drug development

Continuous research and development efforts have led to the discovery of new formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.

Restraint:

Side effects

Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.

Opportunity:

Rising prevalence of epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.

Threat:

Social stigma

Despite advancements in understanding the neurological condition, societal misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.

Covid-19 Impact

The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.

The third generation segment is expected to be the largest during the forecast period

The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.

The Oral segment is expected to have the highest CAGR during the forecast period

The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.

Key players in the market

Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.

Key Developments:

In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types of Seizures Covered:

  • Partial-onset seizures
  • Generalized seizures
  • Other Types of Seizures

Route of Administrations Covered:

  • Intravenous
  • Oral
  • Other Route of Administrations

Drug Generations Covered:

  • First Generation
  • Second Generation
  • Third Generation

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antiepileptic Drugs Market, By Types of Seizures

  • 5.1 Introduction
  • 5.2 Partial-onset seizures
  • 5.3 Generalized seizures
  • 5.4 Other Types of Seizures

6 Global Antiepileptic Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Intravenous
  • 6.3 Oral
  • 6.4 Other Route of Administrations

7 Global Antiepileptic Drugs Market, By Drug Generation

  • 7.1 Introduction
  • 7.2 First Generation
    • 7.2.1 Carbamazepine
    • 7.2.2 Phenytoin
    • 7.2.3 Valproate
    • 7.2.4 Oxycarbazepine
    • 7.2.5 Ethosuximide
    • 7.2.6 Topiramate
    • 7.2.7 Primidone
    • 7.2.8 Phenobarbital
  • 7.3 Second Generation
    • 7.3.1 Pregabalin
    • 7.3.2 Lamotrigine
    • 7.3.3 Levetiracetam
    • 7.3.4 Rufinamide
    • 7.3.5 Eslicarbazepine acetate
    • 7.3.6 Lacosamide
    • 7.3.7 Perampanel
    • 7.3.8 Zonisamide
  • 7.4 Third Generation

8 Global Antiepileptic Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Antiepileptic Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Eisai Co., Ltd.
  • 11.2 Novartis AG
  • 11.3 Merck KGaA
  • 11.4 Teva Pharmaceutical Industries Ltd.
  • 11.5 AstraZeneca
  • 11.6 Abbott
  • 11.7 Sanofi
  • 11.8 Pfizer Inc.
  • 11.9 GlaxoSmithKline plc
  • 11.10 Dr. Reddy's Laboratories Ltd.
  • 11.11 Johnson & Johnson Service, Inc.
  • 11.12 Zogenix
  • 11.13 Alkem Labs
  • 11.14 SK Biopharmaceuticals
  • 11.15 Sun Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Antiepileptic Drugs Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Antiepileptic Drugs Market Outlook, By Types of Seizures (2023-2034) ($MN)
  • Table 3 Global Antiepileptic Drugs Market Outlook, By Partial-onset seizures (2023-2034) ($MN)
  • Table 4 Global Antiepileptic Drugs Market Outlook, By Generalized seizures (2023-2034) ($MN)
  • Table 5 Global Antiepileptic Drugs Market Outlook, By Other Types of Seizures (2023-2034) ($MN)
  • Table 6 Global Antiepileptic Drugs Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 7 Global Antiepileptic Drugs Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 8 Global Antiepileptic Drugs Market Outlook, By Oral (2023-2034) ($MN)
  • Table 9 Global Antiepileptic Drugs Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 10 Global Antiepileptic Drugs Market Outlook, By Drug Generation (2023-2034) ($MN)
  • Table 11 Global Antiepileptic Drugs Market Outlook, By First Generation (2023-2034) ($MN)
  • Table 12 Global Antiepileptic Drugs Market Outlook, By Carbamazepine (2023-2034) ($MN)
  • Table 13 Global Antiepileptic Drugs Market Outlook, By Phenytoin (2023-2034) ($MN)
  • Table 14 Global Antiepileptic Drugs Market Outlook, By Valproate (2023-2034) ($MN)
  • Table 15 Global Antiepileptic Drugs Market Outlook, By Oxycarbazepine (2023-2034) ($MN)
  • Table 16 Global Antiepileptic Drugs Market Outlook, By Ethosuximide (2023-2034) ($MN)
  • Table 17 Global Antiepileptic Drugs Market Outlook, By Topiramate (2023-2034) ($MN)
  • Table 18 Global Antiepileptic Drugs Market Outlook, By Primidone (2023-2034) ($MN)
  • Table 19 Global Antiepileptic Drugs Market Outlook, By Phenobarbital (2023-2034) ($MN)
  • Table 20 Global Antiepileptic Drugs Market Outlook, By Second Generation (2023-2034) ($MN)
  • Table 21 Global Antiepileptic Drugs Market Outlook, By Pregabalin (2023-2034) ($MN)
  • Table 22 Global Antiepileptic Drugs Market Outlook, By Lamotrigine (2023-2034) ($MN)
  • Table 23 Global Antiepileptic Drugs Market Outlook, By Levetiracetam (2023-2034) ($MN)
  • Table 24 Global Antiepileptic Drugs Market Outlook, By Rufinamide (2023-2034) ($MN)
  • Table 25 Global Antiepileptic Drugs Market Outlook, By Eslicarbazepine acetate (2023-2034) ($MN)
  • Table 26 Global Antiepileptic Drugs Market Outlook, By Lacosamide (2023-2034) ($MN)
  • Table 27 Global Antiepileptic Drugs Market Outlook, By Perampanel (2023-2034) ($MN)
  • Table 28 Global Antiepileptic Drugs Market Outlook, By Zonisamide (2023-2034) ($MN)
  • Table 29 Global Antiepileptic Drugs Market Outlook, By Third Generation (2023-2034) ($MN)
  • Table 30 Global Antiepileptic Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 31 Global Antiepileptic Drugs Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 32 Global Antiepileptic Drugs Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 33 Global Antiepileptic Drugs Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 34 Global Antiepileptic Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.